Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6415
    -0.0011 (-0.17%)
     

  • OIL

    83.14
    +0.41 (+0.50%)
     

  • GOLD

    2,411.10
    +13.10 (+0.55%)
     

  • Bitcoin AUD

    100,138.63
    +1,722.23 (+1.75%)
     

  • CMC Crypto 200

    1,382.72
    +70.10 (+5.34%)
     

  • AUD/EUR

    0.6022
    -0.0009 (-0.14%)
     

  • AUD/NZD

    1.0898
    +0.0023 (+0.21%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    16,994.53
    -399.79 (-2.30%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,867.73
    +92.35 (+0.24%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio

Alex Carchidi, The Motley Fool
·4-min read
What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio

The last 12 months haven't been kind to the likes of gene editing stocks like CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE). Whereas CRISPR's shares fell by 31%, Bluebird's are down by 33%. CRISPR Therapeutics is on track to have a transformative 2023, but its biggest risk is that regulators will stymie its efforts to commercialize its gene therapy candidate exa-cel, which aims to treat beta thalassemia and sickle cell disease.

Continue reading